All In Biotech

Drug Trial Radar · NCT01021215

Zileuton With or Without Celecoxib As Chemopreventive Agents in Smokers

Modulation of Arachidonic Acid Metabolism by Chemopreventive Agents in Smokers

Last checked: Nov 20, 2026Latest source record: Apr 2, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

84

Actual

Start

May 2010

Primary completion

Aug 2012

Study completion Mar 2013

Sponsor

Sponsor type
NIH
First posted
Nov 26, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical research study is to learn how zileuton alone or the combination of zileuton and celecoxib may affect certain chemicals in the body that may be linked with a risk for smoking-related lung disease. These effects will be measured by a urine test

Conditions

  • Tobacco Use Disorder

Interventions

  • ZileutonDrug

    1200 mg twice daily given orally (PO) for 6 days

  • CelecoxibDrug

    200 mg twice daily given orally for 6 days

  • laboratory biomarker analysisOther

    Correlative studies

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Median Urinary PGE-M Levels (Pre and Post Treatment)Time frame: Baseline and Day 6
  2. Median Urinary LTE4 Levels (Pre and Post Treatment)Time frame: Baseline and day 6

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Weill Cornell Medical College in New York City, Cornell University

    New York, New York

  • MD Anderson Cancer Center - Consortium Lead Organzation

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.